辰欣药业2025年中报简析：净利润同比下降15.23%

Financial Performance - The company reported a total revenue of 1.74 billion yuan for the first half of 2025, a decrease of 15.97% year-on-year [1] - The net profit attributable to shareholders was 229 million yuan, down 15.23% compared to the previous year [1] - The gross margin was 56.16%, a decline of 2.74% year-on-year, while the net margin increased slightly to 13.29%, up 0.56% [1] - In Q2 2025, total revenue was 820 million yuan, a decrease of 11.07% year-on-year, and net profit was 85.6 million yuan, down 20.33% [1] Key Financial Ratios - The company's return on invested capital (ROIC) was 8.01%, indicating average capital returns [3] - The historical median ROIC since the company went public is 11.34%, with the lowest recorded ROIC at 6.02% in 2022 [3] - The company’s net profit margin for the previous year was 12.93%, suggesting a high added value for its products or services [3] Cost Management - Total selling, administrative, and financial expenses amounted to 563 million yuan, accounting for 32.36% of revenue, a decrease of 7.09% year-on-year [1] - The company has a significant accounts receivable situation, with accounts receivable to profit ratio reaching 135.84% [3] Shareholder Information - The largest fund holding in the company is the Multi-Strategy LOF, with a current scale of 90 million yuan and a recent net value of 1.4275, down 1.94% from the previous trading day [4] - The fund has seen a 22.95% increase over the past year [4]